Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors

Clin Infect Dis. 2020 Jul 11;71(2):422-425. doi: 10.1093/cid/ciz1092.

Abstract

Among prospectively enrolled adult patients with cancer receiving immune checkpoint inhibitors (ICIs; n = 46) or cytotoxic agents (n = 90), seroprotection and seroconversion rates after seasonal quadrivalent influenza vaccinations were higher with ICI than with cytotoxic chemotherapy. These results support annual influenza vaccinations for cancer patients receiving ICIs. Clinical Trials Registration clinicaltrials.gov (NCT03590808).

Keywords: immune checkpoint inhibitor; immune-related adverse event; immunogenicity; influenza; vaccination.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Viral / therapeutic use
  • Humans
  • Immune Checkpoint Inhibitors
  • Influenza Vaccines* / therapeutic use
  • Influenza, Human* / prevention & control
  • Neoplasms* / drug therapy
  • Seroconversion
  • Vaccination

Substances

  • Antibodies, Viral
  • Immune Checkpoint Inhibitors
  • Influenza Vaccines

Associated data

  • ClinicalTrials.gov/NCT03590808